Clinical

Dataset Information

0

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment


ABSTRACT: The presence of a BRAFV600E mutation is a marker of poor prognosis in patients with mCRC and associated with a median overall survival (mOS) of approximately 12 to 14 months compared to 20 to 25 months for patients with BRAF wild-type tumours. After 1st line therapy, treatment outcomes with standard therapy are poor in patients with BRAF-mutated mCRC, with response rates (ORR) of ≤ 11%, a median progression-free survival (mPFS) between 1.8 and 2.8 months, and a mOS between 4.1 and 6.2 months. Failure to achieve adequate survival outcomes with standard treatment regimens in patients with BRAF-mutated mCRC has encouraged efforts to combine multiple targeted therapies: With 665 randomized patients, the BEACON CRC trial represents the largest trial and is currently the only phase III study in patients with BRAFV600E-mutant mCRC. BERING CRC - designed as a prospective (allowing initial retrospective documentation), longitudinal, non-interventional study - will investigate the real-world effectiveness, quality of life, safety and tolerability of encorafenib and cetuximab in BRAFV600E-mutant mCRC patients, who have received prior systemic therapy. Data from this study will contribute to a deeper understanding and characterization to the everyday use of encorafenib and cetuximab in a broader patient population in the German, Austrian, and Swiss routine setting.

DISEASE(S): Carcinoma,Metastatic Colorectal Carcinoma,Colorectal Neoplasms

PROVIDER: 2361171 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-08-29 | PXD042499 | Pride
2023-04-29 | PXD039766 | Pride
| 2333798 | ecrin-mdr-crc
2015-12-31 | E-GEOD-58546 | biostudies-arrayexpress
2012-05-17 | E-GEOD-38026 | biostudies-arrayexpress
| 2537795 | ecrin-mdr-crc
| EGAS00001005973 | EGA
2024-11-06 | GSE269881 | GEO
2024-11-06 | GSE269880 | GEO
2012-05-18 | GSE38026 | GEO